DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



An Observational Study of the Real Life Management of the Psoriasis Patients Treated With Enbrel According to the New Reimbursement Criteria

Information source: Pfizer
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Plaque Psoriasis Patients

Intervention: Enbrel treatment (Other)

Phase: Phase 4

Status: Recruiting

Sponsored by: Pfizer

Official(s) and/or principal investigator(s):
Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer

Overall contact:
Pfizer CT.gov Call Center, Phone: 1-800-718-1021

Summary

With the new reimbursement criteria, we want:

To describe the average treatment duration of patients with Enbrel expressed as a number of weeks/year.

To describe the number of patients who receive continuous treatment To describe the number of patients who receive intermittent treatment To describe the number of weeks off treatment

Clinical Details

Official title: An Observational Study of the Real Life Management of the Psoriasis Patients Treated With Enbrel According to the New Reimbursement Criteria - Beflex Study

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Average treatment duration of patients with Enbrel expressed as a number of weeks/year.

Secondary outcome:

Number of patients who receive continuous treatment

Number of patients who receive intermittent treatment

Number of weeks off treatment

Detailed description: 100 patients will be followed for at least 1 year

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patient restarts or is starting treatment with Enbrel for his/her psoriasis in

alignment with reimbursement criteria

- Patients ≥18 year

- Evidence of a personally signed and dated informed consent document indicating that

the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion Criteria:

N/A

Locations and Contacts

Pfizer CT.gov Call Center, Phone: 1-800-718-1021

Herestraat 49, Leuven 3000, Belgium; Recruiting
Additional Information

To obtain contact information for a study center near you, click here.

Starting date: September 2011
Last updated: January 16, 2013

Page last updated: February 07, 2013

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012